Indoco Remedies Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 19 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.0K Cr
The Company expects noticeable growth in sterile product supply to the US from Q3 FY '26 onwards following US FDA approval to restart two lines (Page 13). The company aims to return to EBITDA margins of around 11%-13% (levels seen pre-remediation issues), with quarter-on-quarter improvement expected.
From Indoco Remedies's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹226
Market Cap
₹2.0K Cr
How does Indoco Remedies rank in Pharmaceuticals & Biotechnology?
Compare Indoco Remedies against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Indoco Remedies — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹476 Cr, net profit ₹-24 Cr.
Full financials →📊 Revenue & Sales Performance
- →The Company expects noticeable growth in sterile product supply to the US from Q3 FY '26 onwards following US FDA approval to restart two lines (Page 13).
- →European sales are anticipated to bounce back to regular levels by Q3 FY '26 after overcoming supply challenges (Page 8).
- →Domestic business showed 10% growth in IQVIA secondary sales with healthy double-digit growth in key segments; expectations are stable or improving (Page 9).
- →OTC business grew over 46% sequentially and is expected to break even in a couple of years with enhanced marketing investments (Page 12).
- →Semi-regulated markets show good growth driven by brand-building and revamped sales strategy, expected to sustain (Page 8).
- →International business showed 26% increase in solid oral exports in Q1 FY '26, indicating positive momentum (Page 4).
- →Incremental efficiency and cost control measures underway suggest improving margins alongside revenue growth (Page 9).
📈 Profitability & Margins
- →The company aims to return to EBITDA margins of around 11%-13% (levels seen pre-remediation issues), with quarter-on-quarter improvement expected.
- →Efforts in cost containment, controlling other expenses, and optimizing CAPEX are underway to improve profitability.
- →Management expects sustained growth in international and domestic markets, with Europe supply resuming fully by Q3 and improvement in semi-regulated markets due to brand building.
- →OTC business is still in investment phase but showed EBITDA break-even in Q1, with expectations to breakeven fully in a couple of years.
- →US market revenue ramp-up is anticipated possibly from Q4 FY '26, after pending FDA inspections and remediation.
- →R&D expenses will be maintained around 5%-5.5% of revenues, with 4-5 filings expected in FY '26 to drive future growth.
- →Debt reduction plans include Rs. 68 crore repayment over next 9 months, improving financial health and interest cost management.
🏗️ Capital Expenditure Plans
- →Current CAPEX is being controlled carefully as per management.
- →Ongoing projects at Goa Plant-2 and the API site for Warren Remedies are underway.
- →Gradual completion of these projects is expected, but not entirely within this year.
- →Incremental CAPEX for the current year is not expected to exceed around Rs. 50 crore.
- →No mention of new or additional strategic investments beyond controlling existing capital expenditure.
💰 Fundraising & Capital Structure
- →No explicit mention of any new fundraising through debt or equity in the current quarter or immediate future.
- →Capital expenditure is being carefully controlled, with only around Rs. 50 crore expected to be spent this year on ongoing projects, indicating no major expansion needing fresh funds.
- →Warren Remedies, which has a negative net worth of Rs. 52 crore, is expected to receive capital infusion in the coming three quarters to strengthen its balance sheet.
- →No capital infusion required for the US subsidiary FPP Holdings, as profitability is expected to improve.
- →Debt repayments planned: about Rs. 68 crore over the next nine months, indicating focus on reducing existing debt rather than raising new debt.
- →Overall, the company appears focused on debt reduction and prudent CAPEX, with no new large fundraising planned currently.
📋 Order Book & Pipeline
- →As per the transcript, Indoco Remedies is currently ramping up manufacturing activities after receiving US FDA approval to restart two lines; however, sales from these sterile products are yet to happen.
- →Full efficiency and rollout of plants, especially post-remediation, are expected by end of Q2 FY '26, with all plants fully operational by Q3 FY '26.
- →The balancing of products and the right number of orders are still being established following last year’s supply disturbances.
- →Europe supply challenges are expected to be overcome by end of Q2 FY '26, with a bounce back in Q3.
- →The US sterile product supply, including complex ophthalmic products like Brinzolamide, is anticipated to potentially start showing revenue impact from Q3 or Q4 FY '26.
- →No explicit numerical orderbook or pending order values were disclosed in the call transcript.
Key Metrics
Continue your research
What Indoco Remedies's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Sigachi Indust. (Q1 FY26)
INR 60 crores from Hyderabad plant in next 6 months, with some recovery from other units (Dahej, Jhagadia). Key concall takeaways from Sigachi Industries Ltd's…
- Sai Life Sciences Ltd (Q1 FY26)
Sai Life Sciences reported a strong Q1 FY'26 with revenue up 77% YoY, driven mainly by CDMO (113% growth) and CRO (38% growth). Key concall takeaways from Sai…
- Cipla Ltd (Q1 FY26)
One Africa business grew 11% YoY, with continued focus on expansion. Key concall takeaways from Cipla's Q1 FY26 earnings call — and how it ranks against sector…
- Anthem Biosciences Ltd (Q1 FY26)
Capacity utilization in custom synthesis is around 70%, with expansions ongoing, indicating potential for further revenue growth. Key concall takeaways from…
Frequently Asked Questions
What were Indoco Remedies Q1 FY26 results?
The Company expects noticeable growth in sterile product supply to the US from Q3 FY '26 onwards following US FDA approval to restart two lines (Page 13). The company aims to return to EBITDA margins of around 11%-13% (levels seen pre-remediation issues), with quarter-on-quarter improvement expected.
What is Indoco Remedies share price analysis?
Indoco Remedies currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹2,026 Cr. Investors should review the full earnings analysis for detailed insights.
Is Indoco Remedies planning capital expenditure?
Current CAPEX is being controlled carefully as per management. - Ongoing projects at Goa Plant-2 and the API site for Warren Remedies are underway. - Gradual completion of these projects is expected, but not entirely within this year. - Incremental CAPEX for the current year is not expected to exceed around Rs.
Keep Indoco Remedies on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.